AUTHOR=Decoin Raphaël , Butruille Laura , Defrancq Thomas , Robert Jordan , Destrait Nicolas , Coisne Augustin , Aghezzaf Samy , Woitrain Eloise , Gouda Zouriatou , Schino Sofia , Klein Cédric , Maboudou Patrice , Brigadeau François , Klug Didier , Vincentelli Andre , Dombrowicz David , Staels Bart , Montaigne David , Ninni Sandro 

TITLE=High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation

JOURNAL=Frontiers in Endocrinology

VOLUME=Volume 13 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.957245

DOI=10.3389/fendo.2022.957245

ISSN=1664-2392

ABSTRACT=Background: A number of epidemiological studies have suggested an association between Metabolic-dysfunction Associated Fatty Liver Disease (MAFLD) and the incidence of atrial fibrillation (AF). However, the pathogenesis leading to AF in the context of MAFLD remains unclear. We therefore aimed at assessing the impact of MAFLD and liver fibrosis status on left atrium (LA) structure and function.
Methods: Patients with a Fatty Liver Index (FLI) >60 and the presence of metabolic comorbidities were classified MAFLD+ . In MAFLD+ patients, liver fibrosis severity was defined using the NAFLD Fibrosis Score (NFS) as follows: MAFLD w/o fibrosis (NFS≦-1.455); MAFLD w/ indeterminate fibrosis (-1.455